2024-10-19 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis

**1. Performance Comparison**

AbbVie Inc. (ABBV) is a pharmaceutical company that develops, manufactures, and markets biopharmaceutical products. 

* **Cumulative Return:** ABBV has generated a cumulative return of 145.47%, outperforming the S&P 500 (VOO) with a cumulative return of 137.88%. 
* **Relative Outperformance:** ABBV is currently outperforming the S&P 500 by 7.59%. This represents a 49.86% percentile ranking in terms of historical outperformance against the S&P 500.

**2. Recent Price Action**

* **Closing Price:** 188.86
* **5-day Moving Average:** 191.08
* **20-day Moving Average:** 193.61
* **60-day Moving Average:** 193.03

The stock is currently trading below its 5, 20, and 60-day moving averages, indicating a potential short-term downtrend.

**3. Technical Indicators**

* **RSI (Relative Strength Index):** 23.77 - This indicates that the stock is currently in oversold territory, suggesting potential for a rebound.
* **PPO (Percentage Price Oscillator):** -0.41 - This signifies a bearish signal as the PPO is below zero, implying that the price momentum is negative.
* **Delta_Previous_Relative_Divergence:** -11.0 - This indicates a short-term downtrend in the relative outperformance against the S&P 500.
* **Expected Return:** 1.95% -  This represents the expected long-term (2 years+) excess return compared to the S&P 500, assuming a buy-and-hold strategy.

**4. Recent Earnings and Outlook**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

The most recent earnings report for the quarter ending July 25, 2024, showed that ABBV beat analysts' expectations, with EPS coming in at $2.65 against an expected $2.57. This positive surprise is likely a contributing factor to the recent stock price action.

**5. News and Recent Issues**

**Recent Market Outlook:** AbbVie's stock has experienced a decline in recent weeks, likely influenced by concerns about the upcoming patent expiration of its blockbuster drug, Humira.  However, analysts anticipate a potential rebound in the near future due to the company's strong pipeline and the ongoing expansion of its portfolio.

**Analyst Opinions:** Despite the patent expiration concerns, analysts generally hold a positive view on ABBV. Many analysts have a "buy" or "strong buy" rating, citing factors like its diversified portfolio, ongoing R&D efforts, and strong cash flow.

**Performance Highlights:** The company recently announced a dividend increase, reinforcing its commitment to shareholder returns. Moreover, its strong track record of earnings growth and consistent dividend payments makes ABBV an attractive option for long-term investors.

**6. Overall Analysis**

ABBV is a pharmaceutical company that has been consistently outperforming the S&P 500. The stock is currently in a short-term downtrend, but technical indicators suggest a potential rebound.  Despite patent expiration concerns for Humira, the company's strong pipeline, consistent earnings growth, and commitment to shareholder returns make it a promising long-term investment opportunity.

**7. English Report**

This analysis suggests that ABBV is a strong contender for long-term investors seeking exposure to the pharmaceutical sector. While the recent market concerns regarding patent expiration are understandable, the company's diversified portfolio, robust earnings, and attractive dividend make it a solid investment choice for those willing to hold for the long term.  However, investors should remain cautious about the potential for short-term volatility and keep a close eye on future news and updates regarding the company's patent strategy and new drug pipeline. 
